X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
A favorable decision from the Federal Court of Canada setting aside second time decision of Canada’s national healthcare regulatory agency, Health Canada, to approve Ruzurgi® (amifampridine) for Lambert-Eaton Myasthenic Syndrome ("LEMS") patients.
Lead Product(s): Amifampridine Phosphate
Therapeutic Area: Immunology Product Name: Ruzurgi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Catalyst Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2022
Details:
KYE Pharmaceuticals announces FIRDAPSE® (amifampridine phosphate), the first amifampridine product approved in Canada, is now widely available for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults.
Lead Product(s): Amifampridine Phosphate
Therapeutic Area: Immunology Product Name: Firdapse
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
Under the terms of the agreement, Catalyst will supply Firdapse® to KYE and KYE will be responsible for promotion, sales, advertisement, marketing, product importation and distribution.
Lead Product(s): Amifampridine Phosphate
Therapeutic Area: Immunology Product Name: Firdapse
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalyst Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
